Abstract 2150
Background
A decrease in AFP level during treatment has been associated with improved overall survival (OS) in patients with HCC. In the phase 3 RESORCE trial (NCT01774344), the multikinase inhibitor regorafenib significantly improved OS versus placebo in patients with HCC and disease progression on sorafenib. We analyzed OS in patients who had an AFP response in RESORCE.
Methods
Patients with Barcelona Clinic Liver Cancer stage B or C HCC, Child -Pugh A liver function, ECOG performance status 0 − 1, and documented radiologic progression on prior sorafenib were randomized 2:1 to regorafenib 160 mg/day (n = 379) or placebo (n = 194) for Weeks 1-3 of each 4-week cycle. Serum AFP levels were assessed at baseline, every 4 weeks during treatment, and at the end of treatment. Patients who had a baseline AFP ≥20 ng/mL and an AFP measurement at the start of Cycle 3 were evaluable for AFP response, defined as a decrease of ≥ 20% in AFP level from baseline at the start of Cycle 3.
Results
Overall, 232 of the 573 randomized patients fulfilled the above criteria and were included in the analysis. Patients with an AFP response had a median OS from randomization of 13.8 months vs 8.9 months in those without an AFP response (Table). The rate of AFP response was 46% (77/168) in the regorafenib group and 11% (7/64) in the placebo group. Among regorafenib-treated patients, the median OS was 13.8 months in patients with an AFP response vs 9.8 months in those without an AFP response. A landmark analysis of OS from the start of Cycle 3 showed that the hazard ratios for AFP response vs no response were 0.57 (95% CI 0.40, 0.82) in the regorafenib and placebo arms combined and 0.72 (95% CI 0.48, 1.08) for patients in the regorafenib arm.Table:
755P
Regorafenib + /placebo arms combined | Regorafenib arm | |||
---|---|---|---|---|
(n = 232) | (n = 168) | |||
AFP response (n = 84) | No AFP response (n = 148) | AFP response (n = 77) | No AFP response (n = 91) | |
Median OS (95% CI) from randomization, months | 13.8 (11.8, 16.5) | 8.9 (8.0, 9.7) | 13.8 (11.7, 16.5) | 9.8 (8.2, 14.2) |
HR (95% CI) AFP response yes/no | 0.57 (0.40, 0.82) | 0.72 (0.48, 1.07) | ||
CI, confidence interval; HR, hazard ratio. |
Conclusions
In this exploratory analysis of RESORCE, an AFP response with regorafenib was associated with improved OS.
Clinical trial identification
NCT01774344.
Editorial acknowledgement
Jennifer Tobin of OPEN Health Medical Communications (London, UK), with financial support from Bayer.
Legal entity responsible for the study
Bayer.
Funding
Bayer.
Disclosure
J. Bruix: Honoraria (self): Bayer; BTG; Eisai; Ipsen; Sirtex; Terumo; Advisory / Consultancy: AbbVie; Adaptimmune; Arqule; Astra-Medimmune; Basilea; Bayer; Bio-Alliance; Bristol-Myers Squibb; BTG; Eisai; Gilead; Incyte; Ipsen; Kowa; Lilly; Merck Sharp & Dohme; Nerviano; Novartis; Quirem; Roche; Sanofi Aventis; Sirtex; Terumo; Research grant / Funding (institution): Bayer; BTG. M. Reig: Honoraria (self): AstraZeneca; Bayer; Bristol-Myers Squibb; BTG; Gilead; Ipsen; Lilly; Advisory / Consultancy: AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Lilly; Roche; Research grant / Funding (institution): Bayer; Travel / Accommodation / Expenses: Bayer; Bristol-Myers Squibb; Gilead; Ipsen; Lilly. P. Merle: Advisory / Consultancy: AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Merck Sharp & Dohme; Onxeo; Roche. M. Kudo: Honoraria (self): Bayer; Eisai; Merck Sharp & Dohme; Advisory / Consultancy: Bayer; Bristol-Myers Squibb; Eisai; Merck Sharp & Dohme; Ono Pharmaceutical; Research grant / Funding (institution): AbbVie; Astellas Pharma; Bristol-Myers Squibb; Chugai; Daiichi Sankyo; EA Pharma; Eisai; Gilead; Medico’s Hirata; Otsuka; Taiho; Takeda. G. Meinhardt: Shareholder / Stockholder / Stock options: Bayer; Full / Part-time employment: Bayer. M. Zhang: Shareholder / Stockholder / Stock options: Bayer; Full / Part-time employment: Bayer. K. Ozgurdal: Full / Part-time employment: Bayer.
Resources from the same session
3875 - Correlation of radiotherapy with the prognosis of elderly patients with hormone receptor-positive breast cancer according to immunohistochemical subtyping
Presenter: Jin Zhang
Session: Poster Display session 2
Resources:
Abstract
5793 - Real world treatment sequencing patterns in secondary breast cancer (SBC): Pathway visualisation using national datasets.
Presenter: Ashley Horne
Session: Poster Display session 2
Resources:
Abstract
3185 - Utilization Pattern of Bone Targeting Agents in Patients with Solid Tumor in Taiwan, Hong Kong and Korea
Presenter: Shi Jie Lai
Session: Poster Display session 2
Resources:
Abstract
3705 - Clinico-pathological Features and Prognosis of Patients with Pregnancy Associated Breast Cancer – A Matched Case Control Study
Presenter: Ruyan Zhang
Session: Poster Display session 2
Resources:
Abstract
1421 - TRYbeCA-2: A Randomized Phase 2/3 Study of Eryaspase in Combination with Gemcitabine and Carboplatin Chemotherapy versus Chemotherapy Alone As First-Line Treatment in Patients with Metastatic or Locally Recurrent Triple-Negative Breast Cancer
Presenter: Ahmad Awada
Session: Poster Display session 2
Resources:
Abstract
4119 - CONTESSA TRIO: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus 3 Different PD-(L)1 Inhibitors in Patients with Metastatic Triple-Negative Breast Cancer (TNBC) and Tesetaxel Monotherapy in Elderly Patients with HER2- Metastatic Breast Cancer (MBC)
Presenter: Sara Tolaney
Session: Poster Display session 2
Resources:
Abstract
4545 - Bintrafusp alfa (M7824) and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer (TNBC)(NCT03579472)
Presenter: Jennifer Litton
Session: Poster Display session 2
Resources:
Abstract
3340 - Effectiveness of Olaparib Plus Trastuzumab in HER2[+], BRCA–mutated (BRCAm) or Homologous Recombination Deficient (HRD) Advanced Breast Cancer (ABC) patients (pts). The OPHELIA Study
Presenter: José Enrique Alés-Martínez
Session: Poster Display session 2
Resources:
Abstract
1113 - RIBOB : A Study on the efficacy and safety of Ribociclib in combination with letrozole in Older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced Breast cancer (aBC) with no prior systemic therapy for advanced disease
Presenter: Cindy Kenis
Session: Poster Display session 2
Resources:
Abstract
4025 - RIbociclib plus Goserelin with Hormonal Therapy versus physician Choice chemotherapy in premenopausal or perimenopausal patients with HR+, HER2– inoperable locally advanced or metastatic breast cancer – RIGHT Choice study
Presenter: Nagi El Saghir
Session: Poster Display session 2
Resources:
Abstract